Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...